Roku (ROKU) closed the last trading session at $61.36, gaining 3.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $88.87 indicates a 44.8% upside potential.The mean estimate comprises 26 short-term price targets with a standard deviation of $17.78. While the lowest estimate of $60 indicates a 2.2% decline from the current price level, the most optimistic analyst expects the stock ...

Group 1 - The stock of Pros Holdings (PRO) closed at $16.87, reflecting a 2.1% gain over the past four weeks, with a mean price target of $28.86 indicating a potential upside of 71.1% [1] - The average price targets from analysts range from a low of $22 to a high of $38, with a standard deviation of $5.98, suggesting a variability in estimates; the lowest estimate indicates a 30.4% increase, while the highest suggests a 125.3% upside [2] - Analysts show a consensus that PRO will report better earnings than previously estimated, which is a positive indicator for potential stock price increases [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 18.9% over the last 30 days, with three estimates moving higher and no negative revisions [12] - PRO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a strong potential for upside in the near term [13] - While price targets may not be entirely reliable, the direction they imply appears to be a good guide for potential price movements [13]

Group 1 - The stock of Priority Technology (PRTH) closed at $6.71, with a 2.1% gain over the past four weeks, and analysts set a mean price target of $12.80, indicating a potential upside of 90.8% [1] - The mean estimate consists of five short-term price targets with a standard deviation of $2.77, where the lowest estimate is $10 (49% increase) and the highest is $16 (138.5% increase) [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price movements [11][12] Group 2 - The Zacks Consensus Estimate for the current year has increased by 1.9% over the past month, indicating positive sentiment among analysts [12] - PRTH holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of the stock's potential gain, it suggests a positive direction for price movement [13]

Core Viewpoint - Jack In The Box (JACK) is expected to report a decline in quarterly earnings and revenues, with analysts predicting earnings of $1.13 per share, a decrease of 22.6% year-over-year, and revenues of $341.22 million, down 6.6% from the previous year [1]. Earnings Estimates - The consensus EPS estimate has been revised downward by 5.6% in the last 30 days, indicating a reassessment by analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate revisions and short-term stock performance [3]. Revenue Projections - Analysts forecast 'Revenues- Franchise' to be $195.16 million, reflecting a decrease of 1.6% from the prior year [5]. - 'Revenues- Company restaurant sales' are expected to reach $147.60 million, indicating an 11.7% decline year-over-year [6]. - 'Revenues- Franchise rental revenues' are projected at $84.39 million, down 1.7% from the previous year [6]. Restaurant Counts - Total system counts for Jack In The Box and Del Taco are estimated at 2,779, down from 2,790 a year ago [7]. - Jack In The Box's total restaurant counts are projected to be 2,189, compared to 2,195 in the same quarter last year [8]. - The estimate for 'Jack in the Box - Restaurant Counts (EOP) - Company' is 154, up from 144 year-over-year [9]. Market Performance - Jack In The Box shares have increased by 9.7% over the past month, while the Zacks S&P 500 composite has risen by 13.7% [10]. - The company holds a Zacks Rank of 3 (Hold), suggesting it is expected to closely follow overall market performance in the near term [11].

Analysts on Wall Street project that Boot Barn (BOOT) will announce quarterly earnings of $1.24 per share in its forthcoming report, representing an increase of 22.8% year over year. Revenues are projected to reach $458.18 million, increasing 18% from the same quarter last year.The consensus EPS estimate for the quarter has been revised 1.6% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this ti ...

Group 1: Financial Performance - InspireMD, Inc. reported a quarterly loss of $0.22 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.17, and compared to a loss of $0.21 per share a year ago, indicating an earnings surprise of -29.41% [1] - The company posted revenues of $1.53 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 9.21%, and showing a slight increase from year-ago revenues of $1.51 million [2] - Over the last four quarters, InspireMD has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Group 2: Stock Performance and Outlook - InspireMD shares have declined approximately 1.1% since the beginning of the year, while the S&P 500 has seen a decline of -3.7% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.18 on revenues of $1.93 million, and for the current fiscal year, it is -$0.79 on revenues of $8.22 million [7] - The estimate revisions trend for InspireMD is mixed, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market in the near future [6] Group 3: Industry Context - The Medical - Instruments industry, to which InspireMD belongs, is currently ranked in the top 28% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

事件：扬农化工发布 2025 年一季报，实现营业收入 32.41 亿元，同比增长 2.04%；归属于上市公司股东的净利润 4.35 亿元，同比微增 1.35%。按 4.07 亿股的总股本计算，实现摊薄每股收益 1.07 元。 行业景气逐步企稳，一季度销量提升情况良好。公司一季度营收同比微增 2.1%，其中原药、制剂、贸易及其他业务营收分别为 18.06、8.71、5.64 亿 元，较去年同期分别增加 0.82 亿元、增加 0.09 亿元、减少 0.26 亿元；其 中原药业务营收增长是收入提升主要原因。 公司报告 | 季报点评 扬农化工（600486） 证券研究报告 一季报业绩符合预期，期待葫芦岛基地投产 辽宁优创建设稳步进行，加快推进创制药成果产出。2024 年，辽宁优创一 期第一阶段项目已经建成，正在陆续进行调试生产，功夫菊酯等多个品种 已拿出合格产品。辽宁优创一期一阶段、二阶段项目相继投产运营，将进 一步优化公司产品布局，形成新的业绩增长点，为公司持续稳健发展奠定 坚实基础。创制药方面，公司自主创制水平居行业领先，在我国自主创制、 年销售额超过亿元的 6 个品种中，公司占居 3 个。公司进一步推动创制化 ...

Core Viewpoint - The company reported a slight increase in revenue for Q1 2025, but net profit experienced a decline due to rising tax rates, indicating mixed performance in financial results [1][2][3]. Revenue and Profitability - Revenue for Q1 2025 reached 1649.3 billion yuan, a year-on-year increase of 2.6%, which is an improvement of 1.4 percentage points compared to 2024 [1][2]. - Net profit attributable to shareholders for Q1 2025 was 543.6 billion yuan, reflecting a year-on-year decrease of 2.9%, a slowdown of 5.5 percentage points compared to 2024 [1][2]. Tax Impact - The effective tax rate for Q1 2025 rose to 20%, an increase of 3.5 percentage points year-on-year, which negatively impacted profit growth [3]. Asset and Loan Growth - Total assets grew by 6.9% year-on-year to 36 trillion yuan, with deposits increasing by 6.2% to 25.6 trillion yuan and loans rising by 8.3% to 22.6 trillion yuan [4]. - New loans in Q1 2025 amounted to 1.01 trillion yuan, an increase of 0.09 trillion yuan compared to the same period last year [4]. Interest Margin - The interest margin decreased by 11 basis points to 1.29% in Q1 2025, primarily due to a larger decline in asset yields compared to improvements in liability costs [5]. - Estimated asset yield fell by 0.3 percentage points to 3.1%, influenced by a general decline in loan rates and LPR repricing [5]. Non-Interest Income - Non-interest income increased by 18.9% year-on-year, with fee income rising by 2.1% [6]. - Other non-interest income surged by 37.3%, with foreign exchange net losses increasing significantly by 668.5% [6]. Asset Quality - The non-performing loan ratio remained stable at 1.25%, with a provision coverage ratio of 198%, indicating steady asset quality [7]. - The core Tier 1 capital adequacy ratio stood at 11.82%, with total capital adequacy at 17.98% [7]. Profit Forecast - The company forecasts net profit attributable to shareholders for 2025, 2026, and 2027 to be 2404 billion, 2453 billion, and 2477 billion yuan respectively, with corresponding EPS of 0.82, 0.83, and 0.84 yuan [8]. - Current stock price corresponds to a price-to-book ratio of 0.64, 0.58, and 0.53 for the respective years, suggesting a "buy" investment rating [8].

Group 1 - Adeia (ADEA) shares have increased by 4.4% over the past four weeks, closing at $13.10, with a mean price target of $17.33 indicating a potential upside of 32.3% [1] - The average price targets range from a low of $17 to a high of $18, with a standard deviation of $0.58, suggesting a relatively high agreement among analysts [2] - Analysts are optimistic about ADEA's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which historically correlates with stock price movements [4][11] Group 2 - The Zacks Consensus Estimate for ADEA's current year earnings has increased by 1% over the past month, with no negative revisions [12] - ADEA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside [13] - While consensus price targets may not be entirely reliable, the direction they imply appears to be a good guide for potential price movement [13]

Group 1 - Si-Bone (SIBN) shares have increased by 25.5% over the past four weeks, closing at $17.47, with a mean price target of $24.67 indicating a potential upside of 41.2% [1] - The mean estimate consists of nine short-term price targets with a standard deviation of $3.57, where the lowest estimate is $19 (an 8.8% increase) and the highest is $32 (an 83.2% increase) [2] - Analysts show strong agreement on SIBN's ability to report better earnings, with a positive trend in earnings estimate revisions correlating with potential stock price increases [4][11] Group 2 - The Zacks Consensus Estimate for SIBN has increased by 7% due to four upward revisions in earnings estimates over the last 30 days, with no negative revisions [12] - SIBN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] - While price targets can be misleading, the direction implied by them may serve as a useful guide for further research into SIBN's fundamentals [10][11]